Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 0.54 |
| ▸ | HTR3A | P46098 | 10/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465829 | 0.89 | HRH4 (0.42) | HRH4HTR3AKDM4ENPSR1 | |
| SCHEMBL404858 | 0.88 | HRH4 (0.51) | HRH4HTR3AKDM4EUSP2ALDH1A1 | |
| SCHEMBL406114 | 0.83 | HRH4 (0.50) | HRH4HTR3AKDM4EUSP2ALDH1A1 | |
| SCHEMBL2528617 | 0.83 | HRH4 (0.56) | HRH4HTR3AKDM4EUSP2ALDH1A1 | |
| SCHEMBL2532972 | 0.79 | HRH4 (0.48) | HRH4HTR3AKDM4EUSP2ALDH1A1 | |
| SCHEMBL405768 | 0.78 | HRH4 (0.65) | HRH4HTR3AKDM4EUSP2ALDH1A1 | |
| SCHEMBL406218 | 0.76 | CETP (0.50) | HRH4HTR3AKDM4ENPSR1HTR6 | |
| SCHEMBL404622 | 0.75 | HRH4 (0.50) | HRH4HTR3AKDM4EUSP2ALDH1A1 | |
| SCHEMBL2464693 | 0.72 | HIF1A (0.45) | HRH4KDM4EUSP2ALDH1A1CASP1 | |
| SCHEMBL405351 | 0.72 | HRH4 (0.52) | HRH4HTR3AKDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 153/4885KDM4E 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.